MedTrace Logo

Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population

NCT07652567 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2026-06-17

No results posted yet for this study

Summary

I. Research Objectives

Primary Objectives:

To evaluate the effect of low-dose antihypertensive therapy on the incidence of new-onset hypertension and new-onset diabetes in individuals with high-normal blood pressure and cardiovascular risk factors.

To assess the impact of low-dose antihypertensive therapy on composite cardiovascular events in individuals with high-normal blood pressure and cardiovascular risk factors.

Secondary Objective:

To evaluate the effects of low-dose antihypertensive therapy and different drug regimens on intermediate markers or subclinical status of cardiovascular disease risk, including lipid profiles, carotid atherosclerosis, and arterial stiffness (pulse wave velocity).

II. Study Population Individuals with high-normal blood pressure and comorbid cardiovascular risk factors who have not been treated with antihypertensive medications.

III. Endpoints

Primary Endpoints:

New-onset hypertension and new-onset diabetes. Composite cardiovascular events (fatal and non-fatal stroke, myocardial infarction, cardiovascular death, and coronary revascularization).

Other Endpoints:

Hospitalization for transient ischemic attack (TIA), hospitalization for angina pectoris, hospitalization for heart failure, peripheral vascular disease, malignancy, all-cause mortality, and renal failure.

Conditions

  • High-normal Blood Pressure

Interventions

DRUG

Telmisartan

Patients will receive Telmisartan 40 mg, administered as one tablet once daily.

DRUG

Indapamide

Patients will receive Indapamide 1.5 mg, administered as one capsule every other day.

OTHER

Placebo

Patients will receive a placebo, administered as half a tablet once daily.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-01
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07652567 on ClinicalTrials.gov